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Pulmonary Hypertension in Heart Failure
With Preserved Ejection Fraction
A Community-Based Study
Carolyn S. P. Lam, MBBS,*† Véronique L. Roger, MD, MPH,* Richard J. Rodeheffer, MD,*
Barry A. Borlaug, MD,* Felicity T. Enders, PHD,‡ Margaret M. Redfield, MD*
Rochester, Minnesota; and Singapore, Singapore
Objectives This study sought to define the prevalence, severity, and significance of pulmonary hypertension (PH) in heart
failure with preserved ejection fraction (HFpEF) in the general community.
Background Although HFpEF is known to cause PH, its development is highly variable. Community-based data are lacking,
and the relative contribution of pulmonary venous versus pulmonary arterial hypertension (HTN) to PH in HFpEF
is unknown. We hypothesized that PH would be a marker of symptomatic pulmonary congestion, distinguishing
HFpEF from pre-clinical hypertensive heart disease.
Methods This community-based study of 244 HFpEF patients (age 76  13 years; 45% male) was followed up using
Doppler echocardiography over 3 years. Control subjects were 719 adults with HTN without HF (age 66  10
years; 44% male). Pulmonary artery systolic pressure (PASP) was derived from the tricuspid regurgitation veloc-
ity and PH defined as PASP 35 mm Hg. Pulmonary capillary wedge pressure (PCWP) was estimated from the
ratio of early transmitral flow velocity to early mitral annular diastolic velocity.
Results In HFpEF, PH was present in 83% and the median (25th, 75th percentile) PASP was 48 (37, 56) mm Hg.
PASP increased with PCWP (r  0.21; p  0.007). Adjusting for PCWP, PASP was higher in HFpEF than HTN
(p  0.001). The PASP distinguished HFpEF from HTN with an area under the receiver-operating characteristic curve
of 0.91 (p  0.001) and strongly predicted mortality in HFpEF (hazard ratio: 1.3 per 10 mm Hg; p  0.001).
Conclusions PH is highly prevalent and often severe in HFpEF. Although pulmonary venous HTN contributes to PH, it does not
fully account for the severity of PH in HFpEF, suggesting that a component of pulmonary arterial HTN also con-
tributes. The potent effect of PASP on mortality lends support for therapies aimed at pulmonary arterial HTN in
HFpEF. (J Am Coll Cardiol 2009;53:1119–26) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.11.051c
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neft-sided heart failure (HF) is known to cause pulmonary
ypertension (PH) (1), but the development and severity of
H in HF is highly variable, and contributing factors are
ot fully understood. Although initial studies focused on
atients with reduced left ventricular ejection fraction (EF)
2), early isolated case reports (3,4) and more recent case
eries (5–7) have shown that PH can occur in heart failure
ith preserved ejection fraction (HFpEF). There is now
rowing appreciation that PH is common and may be severe
n elderly patients with HFpEF (8). However, the true
revalence and severity of PH in HFpEF from the general
rom the *Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota;
Yong Loo Lin School of Medicine, Singapore, Singapore; and the ‡Department of
ealth Sciences Research, Mayo Clinic, Rochester, Minnesota. Supported by
ational Institutes of Health grants HL63281-4, HL72435-2, and HL55502-7.w
Manuscript received August 20, 2008; revised manuscript received November 17,
008, accepted November 30, 2008.ommunity remain unknown. Previous studies were limited
y selection bias, and population-based data have, to date,
een lacking.
See page 1127
Common to left ventricular failure regardless of EF,
ncreased left-sided filling pressure leads to pulmonary
enous hypertension (HTN) and post-capillary PH. In the
resence of preserved systolic function, the development of
ulmonary venous HTN is associated with the severity of
eft ventricular diastolic dysfunction, as has been shown in
atients with aortic stenosis and normal EF (9). Beyond this
ost-capillary contribution to PH, a reactive increase in
ulmonary arterial tone or intrinsic arterial remodeling can
esult in a superimposed pre-capillary component of pulmo-
ary arterial HTN. This has been shown to occur in patients
ith mitral stenosis (10) and HF with reduced EF (11). In
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Pulmonary Hypertension in HFpEF March 31, 2009:1119–26HFpEF without valvular disease,
however, the relative contribu-
tions of these pre- and post-
capillary components to PH are
unclear. A population-based ap-
proach to discerning the role of
PH in HFpEF is to compare
hypertensive patients with and
without HF from the same com-
munity. Because hypertensive
heart disease is the most com-
mon precursor to HFpEF and
because elderly hypertensive pa-
tients without HF often show
Doppler-echocardiographic fea-
tures in common with HFpEF,
comparisons between these groups
of patients can provide insight into
mechanisms mediating the pro-
gression from hypertensive heart
disease to HFpEF and diagnostic
features that distinguish pre-
linical hypertensive heart disease from overt HFpEF
12–14).
We hypothesized that both pulmonary venous HTN
elated to diastolic dysfunction, as well as pulmonary
rterial HTN related to increased arterial tone or vascular
emodeling, would contribute to PH in HFpEF. Further,
e hypothesized that PH would be related to the develop-
ent and severity of clinically significant pulmonary con-
estion, thus distinguishing HFpEF from pre-clinical hy-
ertensive heart disease without overt HF. Accordingly, the
ims of this population-based study were to measure pul-
onary artery systolic pressure (PASP), define the preva-
ence and severity of PH (PASP 35 mm Hg), and assess
he association between PASP and pulmonary venous HTN
n patients with a clinical diagnosis of HFpEF compared
ith hypertensive heart disease without HF from the same
ommunity. Finally, we sought to determine whether PH
as associated with mortality in HFpEF presenting in the
ommunity.
ethods
his study was conducted in Olmsted County, Minnesota,
ith the approval of the Mayo Foundation Institutional
eview Board. All subjects provided written informed
onsent. Although data from these patients have previously
een published (14,15), many of the indexes proposed here
ave not.
tudy Design and Subject Groups
n this population-based observational study, subject groups
ncluded the following.
ypertensive control (HTN) group. A random sample
Abbreviations
and Acronyms
AUC  area under the
curve
COPD  chronic
obstructive pulmonary
disease
EF  ejection fraction
HF  heart failure
HFpEF  heart failure with
preserved ejection fraction
HTN  hypertension
PASP  pulmonary artery
systolic pressure
PCWP  pulmonary
capillary wedge pressure
PH  pulmonary
hypertension
TR  tricuspid
regurgitationn  2,042, studied between June 1997 and September v000) of the Olmsted County, Minnesota, population ages
45 years underwent medical review, echocardiography,
nd spirometry. From this cohort, 719 subjects with a
istory of HTN but without HF (all EF50%) constituted
he HTN group.
FpEF group. Consecutive HFpEF patients (n  244)
ere identified (between September 2003 and October
005) in an Olmsted County, Minnesota, HF surveillance
tudy as previously described (14). Both inpatients and
utpatients were identified by real-time interrogation of
lectronic medical records using natural language processing
echniques. All patients underwent medical review and
chocardiography. The HF diagnosis was validated using
he Framingham criteria, and EF 50% without hemody-
amically significant left-sided valve disease was confirmed
y echocardiography.
oppler Echocardiography
ll echocardiograms were performed by registered diagnos-
ic cardiac sonographers using standardized instruments and
rotocols, and interpreted by a blinded echocardiologist
C.S.P.L. and M.M.R.). All parameters were measured in
riplicate and averaged. In addition to standard M-mode,
-dimensional, and color Doppler imaging, continuous-
ave Doppler examination of tricuspid flow, pulsed-wave
oppler examination of mitral inflow, and Doppler tissue
maging of the medial mitral annulus were performed in
ach subject as previously described (14,15).
etermination of PH. Because PASP is equal to right
entricular systolic pressure in the absence of pulmonary
tenosis, PASP was estimated using Doppler echocardiog-
aphy by calculating the right ventricular to right atrial
ressure gradient during systole, approximated by the mod-
fied Bernoulli equation as 4v2, where v is the velocity of the
ricuspid regurgitation jet in m/s. Right atrial pressure,
stimated based on echocardiographic characteristics of the
nferior vena cava and assigned a standardized value (16),
as then added to the calculated gradient to give PASP.
he PH was defined as PASP 35 mm Hg (17). Echo-
ardiographic estimates of PASP obtained in this fashion
ave been shown to correlate well with invasively measured
alues on right heart catheterization with a sensitivity and
pecificity of 0.79 to 1.0 and 0.6 to 0.98, respectively, for
redicting PH (18).
ssessment of left ventricular diastolic function. The
atio of early transmitral flow velocity (E) to early mitral
nnular (medial) diastolic velocity (e=) was used to estimate
ulmonary capillary wedge pressure (PCWP) ( 11.96 
.596 · E/e=) based on prior Doppler and invasive measure-
ents at our institution (19). This index has also been
hown to reliably detect pulmonary venous HTN in patients
ith elevated echocardiography-derived PASP undergoing
ight heart catheterization (20). Other parameters included
eft atrial volume as calculated by the ellipse formula and left
entricular mass, both indexed to body surface area (21).
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March 31, 2009:1119–26 Pulmonary Hypertension in HFpEFpirometry
pirometry was performed in accordance with recom-
ended techniques (22) and measurements standardized as
ercentages of predicted normal values (23). Chronic ob-
tructive pulmonary disease (COPD) was defined as either a
orced expiratory volume in 1 s to forced vital capacity ratio
f 70% (24) or the presence of a clinical diagnosis of
OPD.
ollow-Up
he HFpEF patients were followed up from baseline
chocardiography at enrollment to death (all-cause mortal-
ty) or last contact, at which time they were censored.
ollow-up was 100% complete with vital status (March
008) determined from the Mayo Clinic registration data-
ase and the Rochester Epidemiology Project death data-
ase, where mortality data on Olmsted County residents are
outinely collected by reviewing community medical
ecords, death certificates, and obituary notices (15).
tatistical Methods
roups were compared using the Pearson chi-square test for
ategorical variables and t test for normally distributed
ontinuous variables. The association between PASP (log
ransformed to satisfy normality assumptions) and PCWP
as investigated by calculating the Pearson correlation
oefficient. Regression analyses were used for adjusted
omparisons, in which the dependent variable was the
ormally distributed continuous (linear least-squares regres-
ion) or categorical (logistic regression) outcome variable of
nterest, whereas factors entered into the model included
ge, sex, PCWP, group (dummy variable), and appropriate
nteraction terms. Receiver-operating characteristic curve
nalyses were used to determine the ability of echocar-
iographic parameters (PASP, E/e=, left atrial volume
ndex, relative wall thickness, left ventricular mass index)
o distinguish HFpEF from HTN. The optimal cutoff value
or each parameter was defined as the value giving the
argest area under the curve (AUC) for the parameter. The
erived mean  standard error AUC for each parameter
as compared with that of PASP using t tests as well as
aired analyses by the method of DeLong et al. (25), with
onferroni correction to control for multiple comparisons.
he effect of PH on survival was assessed by Kaplan-Meier
nalysis. The association of PASP with mortality was assessed
y Cox regression analysis, before and after adjusting for age
nd other echocardiographic parameters. All analyses were
-sided, and significance was judged at p  0.05.
esults
he tricuspid regurgitation (TR) jets were analyzable in 470
65%) of HTN and 203 (83%) of HFpEF patients. Com-
ared with patients in whom TR jets could not be analyzed,
hose with analyzable TR jets were older (age 64  10 years
s. 70 12 years; p 0.001), were more often female (46%s. 60%; p  0.001), had smaller body size (2.08  0.28 m2
s. 1.91  0.25 m2, p  0.001), were more likely to have
oronary artery disease (21% vs. 28%; p  0.029) or chronic
enal disease (glomerular filtration rate 60 ml/min/1.73
2 in 16% vs. 36%; p  0.001), and were similarly likely to
ave diabetes (20% vs. 17%; p  0.36) or COPD (23% vs.
0%; p  0.29).
istribution of PASP and Prevalence of PH
edian (25th, 75th percentile) PASP was 28 (24, 32) mm Hg
n HTN and 48 (37, 56) mm Hg in HFpEF (p 0.001) (Fig.
A) patients; PH was present in 8% (n  38) of HTN and
3% (n  169) of HFpEF (p  0.001) (Fig. 1B) patients.
linical and echocardiographic characteristics of subjects
ith and without PH in each group are provided in Table 1.
n both groups, patients with PH were older and had higher
ystolic blood pressure, wider pulse pressure, higher PCWP,
nd larger left atria compared with those without PH. There
as no difference in left ventricular systolic function (EF,
troke volume index, cardiac index) or structural character-
stics (mass, relative wall thickness, volume) between those
ith and without PH in either group. Among HFpEF
atients, the prevalence of atrial fibrillation, coronary artery
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Figure 1 Cumulative Frequency Distribution of
PASP and Prevalence of PH by Subject Group
In patients with heart failure and preserved ejection fraction (HFpEF) (in red),
the cumulative frequency distribution of pulmonary artery systolic pressure
(PASP) was shifted toward higher pressures (A), whereas the prevalence of
pulmonary hypertension (PH) was markedly increased (B) compared with sub-
jects with hypertension (HTN) (in black) without heart failure in the community.
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Pulmonary Hypertension in HFpEF March 31, 2009:1119–26isease, diabetes, chronic kidney disease, and COPD were
imilarly high in those with and without PH.
ssociation of PASP With PCWP
he PASP increased with PCWP in both HTN and
FpEF (r  0.318 and r  0.209, respectively; both p 
.007) (Fig. 2). After adjusting for PCWP, PASP was still
igher in HFpEF compared with HTN (p  0.001),
uggesting that beyond the post-capillary contribution of
ulmonary venous congestion, a pre-capillary component of
ulmonary arterial HTN contributed to greater PH in
FpEF.
tility of PASP in Distinguishing HFpEF From HTN
he PASP distinguished HFpEF from HTN with an AUC
f 0.91 (p  0.001) and optimal cutoff of 35 mm Hg,
oinciding with the definition of PH (17).The presence of
H (PASP 35 mm Hg) distinguished HFpEF from
TN with a sensitivity of 83% and a specificity of 92%. In
nivariate analysis, other significant distinguishing markers
haracteristics of Subjects With Measurable PASP
Table 1 Characteristics of Subjects With Measurable PASP
HTN
PH Absent
N (% group) 432 (92)
PASP, mm Hg 28 4
Clinical characteristics
Age, yrs 67 10
Male, % 40
Height, m 1.66 0.10
Weight, kg 79.6 16.9
BSA, m2 1.91 0.23
Body mass index, kg/m2 28.8 5.5
Systolic blood pressure, mm Hg 141 21
Diastolic blood pressure, mm Hg 75 11
Pulse pressure, mm Hg 66 18
Heart rate, beats/min 65 11
Hypertension, % 100
Atrial fibrillation, % 5
Coronary artery disease, % 16
Diabetes mellitus, % 10
Chronic kidney disease,† % 29
Chronic obstructive lung disease,‡ % 14
Echocardiographic characteristics
Ejection fraction, % 65 5
Stroke volume/BSA, ml/m2 46.8 9.3
Cardiac index, l/min/m2 3.0 0.7
LV mass/BSA, g/m2 99.6 22.4
Relative wall thickness 0.42 0.07
LV end-diastolic volume/BSA, ml/m2 59.2 12.2
E/e= ratio 9.3 3.3
PCWP, mm Hg 18 2
Left atrial volume/BSA, ml/m2 26.2 7.8
ata are mean  SD. *p  0.05 versus PH absent. †Glomerular filtration rate 60 ml/min/1.73
26]). ‡Forced expiratory volume in 1 s/forced vital capacity 70% (24) or clinical diagnosis.
BSA body surface area; E/e= the ratio of early transmitral flow velocity to early mitral annular
ASP  pulmonary artery systolic pressure; PCWP  pulmonary capillary wedge pressure; PH ncluded E/e=, left atrial size, and relative wall thickness, (hereas left ventricular mass was not a significant distin-
uishing marker (Table 2) (26). The largest AUC was
btained with PASP (Bonferroni-adjusted p 0.01 vs. each
f the other markers in pairwise comparisons) (Fig. 3). In
ultivariate analysis involving the 443 subjects in whom all
arameters were measurable, only PASP and E/e= remained
ignificant markers of HFpEF (odds of HFpEF vs. HTN
.22 higher per 1-mm Hg increase in PASP and 1.15
igher per unit increase in E/e=, respectively; both p 
.001). Excluding patients with atrial fibrillation (n  26 in
TN; n  54 in HFpEF) from the analysis gave similar
esults (data not shown).
ffect of PH on Survival
n HFpEF, there were 84 deaths over a median follow-up of
.8 years (mean 2.4 1.2 years). By Kaplan-Meier analysis,
ortality was higher in those with a PASP above the
edian value of 48 mm Hg (log-rank p  0.002) (Fig. 4).
he presence of PH as defined by PASP above 35 mm Hg
as similarly strongly associated with mortality in HFpEF
HFpEF
PH Present PH Absent PH Present
38 (8) 34 (17) 169 (83)
40 5* 30 3 52 13*
72 9* 74 11 79 12*
32 47 41
1.62 0.08* 1.66 0.10 1.65 0.14
75.3 14.5 84.8 17.9 81.6 23.0
1.83 0.20 1.97 0.24 1.92 0.29
28.8 5.2 30.9 6.3 29.6 7.2
153 27* 125 20 134 24*
75 11 69 13 67 14
78 20* 56 18 67 20*
65 13 68 15 71 16
100 91 97
13* 22 31
21 59 53
13 27 34
43 50 51
21 29 32
65 7 63 5 62 7
48.9 10.5 42.7 10.3 43.2 9.8
3.1 0.8 2.8 0.7 3.0 0.8
107.4 31.0 99.7 27.2 103.3 30.1
0.42 0.08 0.46 0.11 0.45 0.09
60.7 11.1 54.5 11.4 57.4 15.0
12.8 4.7* 15.7 9.8 19.6 9.6*
20 3* 21 6 24 6*
32.7 8.5* 32.1 11.4 38.1 14.3*
tional Kidney Foundation Kidney Disease Outcomes Quality Initiative Clinical Practice Guidelines
y; HFpEF heart failure with preserved ejection fraction; HTN hypertension; LV left ventricular;
ary hypertension.m2 (Nalog-rank p  0.003). Among echocardiographic parame-
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March 31, 2009:1119–26 Pulmonary Hypertension in HFpEFers, only PASP was associated with mortality in HFpEF
unadjusted hazard ratio: 1.28 per 10 mm Hg; p  0.001)
Table 3), and this association persisted after adjustment for
ge (age-adjusted hazard ratio: 1.22 per 10 mm Hg; p 
.005).
ubanalysis Excluding Patients With
OPD and Other Potential Causes of PH
mong subjects with measurable PASP, COPD was
resent in 15% (n  69) of HTN (13 with the clinical
iagnosis of COPD, 67 with abnormal spirometry, 69 with
ither, and 11 with both diagnostic criteria) and 32% (n 
4) of HFpEF (46 with the clinical diagnosis of COPD, 34
ith abnormal spirometry, 64 with either, and 16 with both
iagnostic criteria). Restricting the analysis to patients
ithout COPD (n  401 in HTN; n  139 in HFpEF),
he HFpEF group still had a greater prevalence of PH (83%
s. 8%; p 0.001) and a higher PASP (48 14 mm Hg vs.
8  5 mm Hg; p  0.001) compared with HTN, even after
djusting for age and PCWP (p  0.001). The presence of
H remained a significant predictor of mortality in HFpEF
p  0.018) independent of age (age-adjusted hazard ratio:
.27 per 10 mm Hg increase in PASP; p  0.014).
A further 11 HFpEF patients had other potential causes
f PH (5 with obstructive sleep apnea, 4 with history of
ulmonary embolism, 1 with scleroderma, and 1 with liver
15 25 35 45
20
40
60
80
HTN
HFpEF
p<0.001
PCWP (mmHg)
PA
SP
 
(m
m
H
g)
Figure 2 Association of PASP With
Pulmonary Venous Hypertension
PASP increased with pulmonary capillary wedge pressure (PCWP) in patients
with HFpEF, as well as in subjects with HTN without heart failure, but remained
higher in HFpEF than HTN after adjusting for PCWP (p  0.001). Raw data
points and linear regression line for the association are shown for HFpEF (in
red) and HTN (in black). Abbreviations as in Figure 1.
eceiver-Operating Characteristic Curve of Echocardiographic Para
Table 2 Receiver-Operating Characteristic Curve of Echocardio
Parameter Number Available AUC (Mean 
PASP, mm Hg 673 0.91 0.0
E/e= ratio 808 0.83 0.0
Left atrial volume/BSA, ml/m2 848 0.75 0.0
Relative wall thickness 759 0.60 0.0
LV mass index, g/m2 756 0.52 0.0UC  area under curve; other abbreviations as in Table 1.isease). Excluding these subjects gave similar results, with
greater prevalence of PH (82% vs. 8%; p  0.001) and
igher PASP (47  14 mm Hg vs. 28  5 mm Hg; p 
.001) in HFpEF compared with HTN, even after adjust-
ng for age and PCWP (p  0.001), as well as a negative
mpact of increasing PASP on survival in HFpEF, inde-
endent of age (age-adjusted hazard ratio: 1.28 per 10 mm
g increase in PASP; p  0.019).
iscussion
n these first population-based data regarding pulmonary
ressures in HFpEF, PH was highly prevalent and often
evere in HFpEF presenting in the general community. The
evelopment of PH was related to the extent of pulmonary
enous HTN as estimated by Doppler indexes. However,
fter accounting for this post-capillary component of PH,
he severity of PH in HFpEF still exceeded that of hyper-
ensive control subjects without HF from the same com-
unity, suggesting the contribution of a pre-capillary com-
onent of pulmonary arterial HTN to PH in HFpEF. The
everity of PH distinguished HFpEF from hypertensive
ontrol subjects with excellent diagnostic accuracy, superior
o traditional indexes of cardiac remodeling (left atrial
rs Distinguishing HFpEF From HTN
ic Parameters Distinguishing HFpEF From HTN
p Value Optimal Cutoff Sensitivity Specificity
0.001 35 83 92
0.001 12.5 70 85
0.001 29 66 74
0.001 0.39 80 36
0.497 105 42 68
0.0 0.2 0.4 0.6 0.8 1.0
0.0
0.2
0.4
0.6
0.8
1.0
Line of no information
Left atrial volume index
E/e' ratio
Left ventricular mass index
Relative wall thickness
PASP
1-Specificity
Se
n
si
tiv
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p<0.01
*vs line of no 
information;
†vs PASP
*†
*†
*†
†
*
Figure 3
Receiver-Operating Characteristic
Curves of Echocardiographic
Parameters for the Diagnosis of HFpEF
By receiver-operating characteristic curve analysis, echocardiographic parame-
ters that distinguished HFpEF from HTN heart disease without heart failure
included PASP, the ratio of early transmittal flow velocity to early mitral annular
diastolic velocity (E/e=), left atrial volume index, and relative wall thickness.
The largest area under curve was obtained with PASP, with the optimal cutoff
value of 35 mm Hg. Abbreviations as in Figure 1.mete
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SE)
2
2
2
3
3
v
i
t
a
T
f
s
P
s
i
H
i
e
e
w
g
d
t
p
P
i
m
a
b
e
s
i
c
m
c
M
H
d
v
w
t
o
P
a
fi
g
d
H
w
a
P
s
P
p
n
i
m
i
t
c
s
p
l
b
o
p
i
s
t
n
f
D
r
P
*
1124 Lam et al. JACC Vol. 53, No. 13, 2009
Pulmonary Hypertension in HFpEF March 31, 2009:1119–26olume, relative wall thickness, left ventricular mass) and of
ncremental value to Doppler indexes of diastolic dysfunc-
ion (E/e=). Further, the presence of PH was a potent
dverse prognostic factor in HFpEF, independent of age.
he implications of these data for PH as a pathophysiologic
actor and therapeutic target in HFpEF deserve further
tudy.
revalence and significance of PH in HFpEF. That
evere PH could develop in HFpEF was described in early
solated case reports of elderly hypertensive patients with
FpEF (3,4). In a subsequent series of patients hospitalized
n the New York metropolitan area for HFpEF, Klapholz
t al. (5) reported a mean PASP of 47  17 mm Hg by
chocardiography in the 44% (272 of 619) of patients in
hom measurements were available. More recently, Kjaer-
aard et al. (7) obtained PASP measurements by echocar-
iography in 38% (388 of 1,022) of Danish patients hospi-
alized for symptomatic HF, 25% (n  96) of whom had
reserved EF, and found a median (25th, 75th percentile)
ASP of 39 (31, 50) mm Hg. Of note, the latter study also
dentified elevated PASP as an independent predictor of
ortality in HFpEF. Although important, the generaliz-
bility of these previous findings was limited by selection
ias and the low proportions of patients in whom PASP
0 1 2 3
0.2
0.4
0.6
0.8
1.0
Number remaining
PASP<48 mmHg 98           86             80             44
PASP≥48 mmHg 105         78    67    38
p=0.002
PASP<48
mmHg
PASP≥48
mmHg
Years
Su
rv
iv
a
l
Figure 4 Kaplan-Meier Survival Curves in HFpEF
Patients With PASP Above and Below the Median
HFpEF patients with PASP above the median value of 48 mm Hg (in red) had
reduced survival compared with patients with PASP 48 mm Hg (in black) over
3 years (log-rank p  0.002). Abbreviations as in Figure 1.
redictors of Mortality in HFpEF
Table 3 Predictors of Mortality in HFpEF
Variable
Univariate Analysis*
n Hazard Ratio
PASP, mm Hg 203 1.28 per 10 mm Hg
E/e= ratio 208 1.01 per U
Left atrial volume/BSA, ml/m2 185 1.12 per 10 ml/m2
Relative wall thickness 211 1.18 per 0.1 U
LV mass index, g/m2 207 1.00 per 10 g/m2Cox regression analysis, in which multivariate model includes all 5 variables.
Abbreviations as in Table 1.stimates were available. Our current findings therefore
erve to confirm and extend the prior studies by including all
npatients and outpatients with HFpEF presenting in the
ommunity, thus providing the first community-based esti-
ates of the prevalence, severity, and prognostic signifi-
ance of PH in HFpEF to date.
echanism of PH in HFpEF. The development of PH in
FpEF has largely focused on the role of left ventricular
iastolic dysfunction and the passive effect of pulmonary
enous HTN. Aragam et al. (9) showed that in patients
ith aortic stenosis, most of whom had normal EF, it was
he severity of diastolic dysfunction, rather than the severity
f aortic stenosis, that correlated better with the severity of
H. Kessler et al. (3) attributed the reversible severe PH in
n elderly hypertensive man to abnormal left ventricular
lling that was treated with long-acting nifedipine. Kjaer-
aard et al. (7) alluded to the contribution of diastolic
ysfunction to PH by showing that HF patients (25%
FpEF) with restrictive filling had higher PASP compared
ith those with nonrestrictive patterns. Finally, Bouchard et
l. (27) showed a close correlation between PASP and
CWP by echocardiography in 69 patients with normal
ystolic function (not all with HF) and concluded that
ASP could be used as a surrogate of left ventricular filling
ressure when pulmonary vascular resistance was assumed
ormal. Our data, while consistent with the prior data,
mportantly highlight that the passive contribution of pul-
onary venous HTN may not by itself account for the
ncreased PASP in HFpEF compared with elderly hyper-
ensive subjects without overt HF. Beyond this post-
apillary component of PH, we postulate that the greater
everity of PH in HFpEF may be caused by an additional
re-capillary component of pulmonary arterial HTN. In
ongstanding pulmonary congestion, pre-capillary PH may
e mediated by reactive increases in pulmonary arterial tone
r development of a congestive arteriopathy characterized by
ulmonary arteriolar remodeling, medial hyperplasia, and
ntimal fibrosis, as shown to occur in patients with mitral
tenosis (10) or systolic HF (11). The presence of PH may
herefore carry important clinical implications for the diag-
osis and treatment of the syndrome as elaborated in the
ollowing text.
iagnostic utility. The difficulties and controversies sur-
ounding the optimal diagnostic approach to HFpEF have
Multivariate Analysis*
p Value n Hazard Ratio p Value
0.001 136 1.20 per 10 mm Hg 0.028
0.496 136 0.98 per U 0.199
0.140 136 1.12 per 10 ml/m2 0.237
0.108 136 1.26 per 0.1 U 0.121
0.946 136 0.96 per 10 g/m2 0.383
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March 31, 2009:1119–26 Pulmonary Hypertension in HFpEFeen the subject of recent debate (28,29). In the most
urrent consensus statement from the European Society of
ardiology (30), a variety of echocardiographic markers of
iastolic dysfunction (chiefly the mitral E/e= ratio) or
ardiac remodeling (left atrial size, left ventricular mass)
ere proposed to aid in the diagnosis of HFpEF. However,
he specificity of these markers has been questioned, because
lderly hypertensive patients frequently show abnormal
itral Doppler profiles and cardiac remodeling in the
bsence of clinical HF (15). As shown in our study and
thers (27), PASP elevation was a good surrogate measure
f clinically significant pulmonary venous HTN in HFpEF.
he present data further showed the utility of PH in
istinguishing HFpEF from HTN independent of E/e=, as
ell as its potent independent impact on survival, suggesting
hat PH may play a primary role in the pathophysiology of
FpEF. Importantly, these findings need to be prospec-
ively validated in other populations, ideally using invasive
old-standard measurements.
herapeutic implications. The presence of a pre-capillary
omponent in addition to post-capillary PH in HFpEF
aises the potential that aside from therapies aimed at
educing pulmonary venous congestion, those aimed at
ulmonary arterial HTN may also have a role in the
reatment of HFpEF. To date, there are no proven therapies
n HFpEF. Treatment recommendations as outlined in HF
uidelines are empiric and have not changed over time.
pecific therapy aimed at PH in HFpEF is therefore an
ppealing consideration but has been tempered by concern
hat increases in right heart output with pulmonary vasodi-
ators may result in further increases in left atrial pressure in
atients with left heart disease and HF (31). Indeed, the use
f epoprostenol was associated with increased mortality in
ystolic HF (32), although the mechanism for increased
ortality was unclear. Similarly, despite early data showing
he deleterious effect of endothelin and potential benefit of
ndothelin antagonism in HF, a trial of the selective
ndothelin receptor A antagonist darusentan in systolic HF
ailed to show clinical benefit (33). However, there remains
oom for cautious optimism. Recent seminal trials using
hosphodiesterase-5 inhibitors in systolic HF (34,35) have
hown beneficial effects, including improvement in exercise
apacity and quality of life. In fact, evidence exists that
hosphodiesterase-5 inhibition may not only improve pulmo-
ary tone and right heart function but also exert pleiotropic
ffects on left ventricular structure (36), ventricular function
36,37), and peripheral vascular function (38). These data lend
upport for the ongoing trial of phosphodiesterase-5 inhibition
n HFpEF (the RELAX [Phosphodiesterase-5 Inhibition to
mprove Clinical Status and Exercise Capacity in Diastolic Heart
ailure] trial [39]).
tudy limitations. The feasibility of obtaining tricuspid
egurgitation signals may potentially have led to overesti-
ation of the prevalence of PH, but estimations of PASP
ere obtained in the majority of subjects including a larger
roportion of participants than in previous studies. Al-hough known causes of PH were excluded by careful
linical review in the subanalyses, occult diagnoses may have
een missed in some patients. Lack of invasive measure-
ents of pulmonary artery characteristic impedance or
ulmonary arteriolar resistance precluded assessment of
ulmonary artery stiffening or pulmonary arteriolar tone.
owever, this study could not have been performed using
n invasive approach. The potential limited precision of
chocardiography-derived PASP is acknowledged (18).
imilarly, although the E/e= ratio provides an estimate of
CWP (19), it is not a perfect measure of PCWP. Further,
esting measures of PCWP do not reflect activity related
ncreases in PCWP that may contribute to reactive PH and
ongestive pulmonary arterial remodeling and weaken the
orrelation between resting PCWP and PASP. Finally, the
ingle time-point measurements in this study did not allow
ssessment for time-dependence of PASP in Cox regression
nalysis and may have led to underestimation of the prog-
ostic significance of PH.
onclusions
ulmonary HTN is common and can be severe in HFpEF
resenting in the community. In addition to pulmonary
enous HTN from diastolic dysfunction, a component of
ulmonary arterial HTN may contribute to PH in HFpEF,
istinguishing these patients from hypertensive control
ubjects without HF. The potent association between PH
nd mortality suggests that PH may contribute to the
rogression of HF in patients with HFpEF, and thus PH
ay represent a therapeutic target in HFpEF.
cknowledgment
he authors thank Brian D. Lahr (Department of Biosta-
istics, Mayo Clinic, Rochester, Minnesota) for his assis-
ance with statistical analysis.
eprint requests and correspondence: Dr. Margaret M. Red-
eld, 200 First Street SW, Rochester, Minnesota 55905. E-mail:
edfield.margaret@mayo.edu.
EFERENCES
1. Thompson W, White PD. Commonest cause of hypertrophy of the
right ventricle-left ventricular strain and failure. Am Heart J 1936;12:
641–9.
2. Abramson SV, Burke JF, Kelly JJ Jr., et al. Pulmonary hypertension
predicts mortality and morbidity in patients with dilated cardiomyop-
athy. Ann Intern Med 1992;116:888–95.
3. Kessler KM, Willens HJ, Mallon SM. Diastolic left ventricular
dysfunction leading to severe reversible pulmonary hypertension. Am
Heart J 1993;126:234–5.
4. Willens HJ, Kessler KM. Severe pulmonary hypertension associated
with diastolic left ventricular dysfunction. Chest 1993;103:1877–83.
5. Klapholz M, Maurer M, Lowe AM, et al. Hospitalization for heart
failure in the presence of a normal left ventricular ejection fraction:
results of the New York Heart Failure Registry. J Am Coll Cardiol
2004;43:1432–8.
6. Ghali JK, Kadakia S, Cooper RS, Liao YL. Bedside diagnosis of
preserved versus impaired left ventricular systolic function in heart
failure. Am J Cardiol 1991;67:1002–6.
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
K
1126 Lam et al. JACC Vol. 53, No. 13, 2009
Pulmonary Hypertension in HFpEF March 31, 2009:1119–267. Kjaergaard J, Akkan D, Iversen KK, et al. Prognostic importance of
pulmonary hypertension in patients with heart failure. Am J Cardiol
2007;99:1146–50.
8. Shapiro B, Nishimura R, McGoon M, Redfield M. Diagnostic
dilemmas: diastolic heart failure causing pulmonary hypertension,
pulmonary hypertension causing diastolic dysfunction. Adv Pulmon
Hypertens 2006;5:13–20.
9. Aragam JR, Folland ED, Lapsley D, Sharma S, Khuri SF, Sharma
GV. Cause and impact of pulmonary hypertension in isolated aortic
stenosis on operative mortality for aortic valve replacement in men.
Am J Cardiol 1992;69:1365–7.
0. Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary hyper-
tension in chronic heart failure: the role of the endothelium in
pathophysiology and management. Circulation 2000;102:1718–23.
1. Delgado JF, Conde E, Sanchez V, et al. Pulmonary vascular remod-
eling in pulmonary hypertension due to chronic heart failure. Eur
J Heart Fail 2005;7:1011–6.
2. Maurer MS, El Khoury Rumbarger L, King DL. Ventricular volume
and length in hypertensive diastolic heart failure. J Am Soc Echocar-
diogr 2005;18:1051–7.
3. Melenovsky V, Borlaug B, Rosen B, et al. Cardiovascular features of
heart failure with preserved ejection fraction versus non-failing hyper-
tensive left ventricular hypertrophy in the urban Baltimore community.
J Am Coll Cardiol 2007;49:198–207.
4. Lam CS, Roger VL, Rodeheffer RJ, et al. Cardiac structure and
ventricular-vascular function in persons with heart failure and pre-
served ejection fraction from Olmsted County, Minnesota. Circulation
2007;115:1982–90.
5. Redfield MM, Jacobsen SJ, Burnett JC Jr., Mahoney DW, Bailey KR,
Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction
in the community: appreciating the scope of the heart failure epidemic.
JAMA 2003;289:194–202.
6. Ommen SR, Nishimura RA, Hurrell DG, Klarich KW. Assessment of
right atrial pressure with 2-dimensional and Doppler echocardiogra-
phy: a simultaneous catheterization and echocardiographic study.
Mayo Clin Proc 2000;75:24–9.
7. Rich SE. Executive summary from the World Symposium on Primary
Pulmonary Hypertension, Evian, France, September 6–10, 1998.
Geneva: The World Health Organization.
8. McGoon M, Gutterman D, Steen V, et al. Screening, early detection,
and diagnosis of pulmonary arterial hypertension: ACCP evidence-
based clinical practice guidelines. Chest 2004;126:14S–34S.
9. Ommen SR, Nishimura RA, Appleton CP, et al. Clinical utility of
Doppler echocardiography and tissue Doppler imaging in the estima-
tion of left ventricular filling pressures: A comparative simultaneous
Doppler-catheterization study. Circulation 2000;102:1788–94.
0. Willens HJ, Chirinos JA, Gomez-Marin O, et al. Noninvasive
differentiation of pulmonary arterial and venous hypertension using
conventional and Doppler tissue imaging echocardiography. J Am Soc
Echocardiogr 2008;21:715–9.
1. Lang RM, Bierig M, Devereux RB, et al. Recommendations for
chamber quantification. Eur J Echocardiogr 2006;7:79–108.
2. Standardization of Spirometry, 1994 Update. American Thoracic
Society. Am J Respir Crit Care Med 1995;152:1107–36.
3. Miller A, Thornton JC, Warshaw R, Bernstein J, Selikoff IJ, Teirstein
AS. Mean and instantaneous expiratory flows, FVC and FEV1:
prediction equations from a probability sample of Michigan, a large
industrial state. Bull Eur Physiopathol Respir 1986;22:589–97.
4. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global
strategy for the diagnosis, management, and prevention of chronic fobstructive pulmonary disease. NHLBI/WHO Global Initiative for
Chronic Obstructive Lung Disease (GOLD) Workshop summary.
Am J Respir Crit Care Med 2001;163:1256–76.
5. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas
under two or more correlated receiver operating characteristic curves: a
nonparametric approach. Biometrics 1988;44:837–45.
6. National Kidney Foundation. K/DOQI Clinical Practice Guidelines.
Available at: www.kidney.org/professionals/kdoqi/guidelines.cfm. Ac-
cessed January 1, 2009.
7. Bouchard JL, Aurigemma GP, Hill JC, Ennis CA, Tighe DA.
Usefulness of the pulmonary arterial systolic pressure to predict
pulmonary arterial wedge pressure in patients with normal left ven-
tricular systolic function. Am J Cardiol 2008;101:1673–6.
8. Maurer MS, Spevack D, Burkhoff D, Kronzon I. Diastolic dysfunc-
tion: can it be diagnosed by Doppler echocardiography? J Am Coll
Cardiol 2004;44:1543–9.
9. Oh JK, Hatle L, Tajik AJ, Little WC. Diastolic heart failure can be
diagnosed by comprehensive two-dimensional and Doppler echocar-
diography. J Am Coll Cardiol 2006;47:500–6.
0. Paulus WJ, Tschope C, Sanderson JE, et al. How to diagnose diastolic
heart failure: a consensus statement on the diagnosis of heart failure
with normal left ventricular ejection fraction by the Heart Failure and
Echocardiography Associations of the European Society of Cardiol-
ogy. Eur Heart J 2007;28:2539–50.
1. Semigran MJ, Cockrill BA, Kacmarek R, et al. Hemodynamic effects
of inhaled nitric oxide in heart failure. J Am Coll Cardiol 1994;24:
982–8.
2. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled
trial of epoprostenol therapy for severe congestive heart failure: The
Flolan International Randomized Survival Trial (FIRST). Am Heart J
1997;134:44–54.
3. Anand I, McMurray J, Cohn JN, et al., EARTH Investigators.
Long-term effects of darusentan on left-ventricular remodelling and
clinical outcomes in the Endothelin A Receptor Antagonist Trial in
Heart Failure (EARTH): randomised, double-blind, placebo-
controlled trial. Lancet 2004;364:347–54.
4. Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD. Long-term
use of sildenafil in the therapeutic management of heart failure. J Am
Coll Cardiol 2007;50:2136–44.
5. Lewis GD, Shah R, Shahzad K, et al. Sildenafil improves exercise
capacity and quality of life in patients with systolic heart failure and
secondary pulmonary hypertension. Circulation 2007;116:1555–62.
6. Takimoto E, Champion HC, Li M, et al. Chronic inhibition of cyclic
GMP phosphodiesterase-5A prevents and reverses cardiac hypertro-
phy. Nat Med 2005;11:214–22.
7. Borlaug BA, Melenovsky V, Marhin T, Fitzgerald P, Kass DA.
Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in
humans. Circulation 2005;112:2642–9.
8. Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S.
Acute type 5 phosphodiesterase inhibition with sildenafil enhances
flow-mediated vasodilation in patients with chronic heart failure. J Am
Coll Cardiol 2000;36:845–51.
9. Phosphodiesterase-5 Inhibition to Improve Clinical Status and
Exercise Capacity in Diastolic Heart Failure (RELAX). Available
at: http://clinicaltrials.gov/ct2/show/NCT00763867?term
Phosphodiesterase-5InhibitiontoImproveClinical&rank1.
Accessed March 3, 2009.
ey Words: pulmonary hypertension y diastolic heart failure y heart
ailure with preserved ejection fraction.
